DermTech Announces Release Date for Fourth-quarter 2023 Financial Results
13 Février 2024 - 2:05PM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a
leader in precision dermatology enabled by a non-invasive skin
genomics technology, will host a conference call and webcast on
Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to
discuss the Company's fourth-quarter 2023 operating and financial
results. In advance of the call on February 29, 2024, DermTech will
issue its fourth-quarter 2023 earnings press release.
For participants interested in asking questions during the
teleconference, please register using the following link. After
registering for the event, a confirmation e-mail will be sent with
a meeting invitation and access information. Registration is open
during the live teleconference, but advance registration is
advised.
Conference Call Registration
For participants interested in listening only, please register
for the webcast using the following link.
Webcast Registration
For those unable to participate in the live call and webcast, a
webcast replay will be available on the Company’s website shortly
after the conclusion of the call.
About DermTech
DermTech is a leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by its non-invasive skin genomics technology. DermTech’s mission is
to improve the lives of millions by providing non-invasive
precision dermatology solutions that enable individualized care.
DermTech provides genomic analysis of skin samples collected using
its Smart Stickers™. DermTech develops and markets products that
facilitate the assessment of melanoma. For additional information,
please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
"outlook," “anticipate,” “intend,” “plan,” “strive," “may,” “will,”
“could,” “should,” “believe,” “predict,” “potential,” “continue,”
and similar expressions are intended to identify such
forward-looking statements. These forward-looking statements
include, without limitation, expectations and evaluations with
respect to: the performance, patient benefits, cost- effectiveness,
commercialization and adoption of DermTech’s products and the
market opportunity for these products; expectations regarding
DermTech’s potential growth, scale, patient reach, financial
outlook and future financial performance DermTech’s ability to
increase its test volume, revenue and the proportion of reimbursed
billable tests; and expectations regarding agreements with or
reimbursement or cash collection patterns from government payers
(including Medicare) or commercial payers and related billing
practices or number of covered lives. These forward-looking
statements involve significant risks and uncertainties that could
cause the actual results to differ materially from the expected
results. Most of these factors are outside of the control of
DermTech and are difficult to predict. Factors that may cause such
differences include, but are not limited to: (1) the outcome of any
legal proceedings that may be instituted against DermTech; (2)
DermTech’s ability to obtain additional funding to develop and
market its products; (3) the existence of favorable or unfavorable
clinical guidelines for DermTech’s tests; (4) the reimbursement of
DermTech’s tests by government payers (including Medicare) and
commercial payers; (5) the ability of patients or healthcare
providers to obtain coverage of or sufficient reimbursement for
DermTech’s products; (6) DermTech’s ability to grow, manage growth
and retain its key employees and maintain or improve its operating
efficiency and reduce operating expenses; (7) changes in applicable
laws or regulations; (8) the market adoption and demand for
DermTech’s products and services together with the possibility that
DermTech may be adversely affected by other economic, business,
and/or competitive factors; and (9) other risks and uncertainties
included in the “Risk Factors” section of the most recent Annual
Report on Form 10-K filed by DermTech with the Securities and
Exchange Commission (the “SEC”), and other documents filed or to be
filed by DermTech with the SEC, including subsequently filed
reports. DermTech cautions that the foregoing list of factors is
not exclusive. You should not place undue reliance upon any
forward- looking statements, which speak only as of the date made.
DermTech does not undertake or accept any obligation or undertaking
to release publicly any updates or revisions to any forward-looking
statements to reflect any change in its expectations or any change
in events, conditions, or circumstances on which any such statement
is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240213675452/en/
Steve Kunszabo DermTech (858) 291-1647
steve.kunszabo@dermtech.com
DermTech (NASDAQ:DMTK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
DermTech (NASDAQ:DMTK)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024